aTyr Pharma, Inc.
ATYRHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeaTyr Pharma, Inc. aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and. Valued at $16.2M, ATYR is a micro-cap name in its sector. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
Market Cap
$16.2M
Beta
0.91
P/E (TTM)
—
P/E (Fwd)
-0.35
EPS (TTM)
$-0.62
EPS (Fwd)
$-0.47
ROE
-98.7%
ROA
-46.6%
Cash
$57.4M
Total Debt
$11.3M
Free CF
-$31.7M
52W Change
-83.0%
Annual Financials
Cash vs Debt
Where ATYR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ATYR finished 69.64% below its 150-day moving average ($0.56) and 73.02% below its 200-day moving average ($0.63). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ATYR overbought or oversold?
At the October 20, 2026 close, ATYR's RSI(14) was 2.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
aTyr Pharma, Inc. holds $57.4M in cash against $11.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$31.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -98.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $10.4M (2022) to $190K (2025), a 98% decline worth watching.
With cash comfortably exceeding debt, ATYR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ATYR.